SCHEMBL29774602

SCHEMBL29774602

O=C1Nc2ccc(Cc3ccc(CN4CCOCC4)c(F)c3)c3cccc1c23

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 5/20 0.48
HSD17B10 Q99714 3/20 0.48
CASP1 P29466 2/20 0.48
CASP7 P55210 2/20 0.48
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
RORC P51449 1/20 0.42
CYP2A13 Q16696 2/20 0.41
TNKS O95271 1/20 0.39
BDKRB1 P46663 1/20 0.39
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
PARP1 P09874 2/20 0.38
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.37
TYMS P04818 2/20 0.36
CDK5 Q00535 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22532771 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL29380591 0.88 KDM4E (0.54) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL22532952 0.88 KDM4E (0.54) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL29774574 0.85 KDM4E (0.51) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL22549630 0.83 MAPT (0.38) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL22532638 0.82 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL29774559 0.82 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL22533363 0.81 ADRA1D (0.49) ALDH1A1GLAGAAALOX15PARP1
SCHEMBL22533487 0.78 ALDH1A1 (0.42) ALDH1A1KDM4EHSD17B10GLAGAA
SCHEMBL22533051 0.77 ADRA1D (0.47) ALDH1A1KDM4EHSD17B10GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 ALDH1A1 3827/4885KDM4E 315/4885HSD17B10 3566/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 ALDH1A1 3827/4885KDM4E 315/4885HSD17B10 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.